Table 2.
Baseline demographic and clinical characteristics of patients with MS newly initiating a DMD
| Characteristics | Self-injectable DMD |
Oral DMD |
P-value |
|---|---|---|---|
| n | 7,207 | 1,175 | – |
| Age, years, mean | 43.0 | 44.9 | <0.0001 |
| Age group, years, n (%) | <0.0001 | ||
| 18–34 | 1,654 (22.9) | 187 (15.9) | |
| 35–44 | 2,217 (30.8) | 352 (30.0) | |
| 45–54 | 2,201 (30.5) | 428 (36.4) | |
| 55–64 | 1,135 (15.7) | 208 (17.7) | |
| Female, n (%) | 5,531 (76.7) | 895 (76.2) | 0.6825 |
| Region, n (%) | 0.7851 | ||
| Northeast | 2,240 (31.1) | 368 (31.3) | |
| Midwest | 2,409 (33.4) | 376 (32.0) | |
| South | 2,151 (29.8) | 362 (30.8) | |
| West | 407 (5.6) | 69 (5.9) | |
| CCI score, mean | 0.55 | 0.48 | 0.0242 |
| Select comorbidities, n (%) | |||
| Anxiety | 940 (13.0) | 149 (12.7) | 0.7789 |
| Arthritis (RA/OA) | 556 (7.7) | 87 (7.4) | 0.7676 |
| Depression | 410 (5.7) | 78 (6.6) | 0.2017 |
| Diabetes | 568 (7.9) | 80 (6.8) | 0.2162 |
| Gastrointestinal diseasea | 1,227 (17.0) | 234 (19.9) | 0.0180 |
| Hypertension | 1,715 (23.8) | 255 (21.7) | 0.1193 |
| Thyroid disease | 1,117 (15.5) | 180 (15.3) | 0.8962 |
Notes: Due to rounding, percentages do not always equal 100%.
a
Includes constipation, diarrhea, dysphagia, gastroesophageal reflux disease, and irritable bowel syndrome.
Abbreviations: CCI, Charlson Comorbidity Index; DMD, disease-modifying drug; MS, multiple sclerosis; OA, osteoarthritis; RA, rheumatoid arthritis.